Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00704R109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| ANL Talent Ltd 13G | 7.8% |
1/16/2026
Event 12/31/2025
|
||
|
Cormorant Asset Management, LP
13G/A
|
6.8% |
8/14/2026
Event 6/30/2026
|
||
| Cormorant Asset Management, LP | 6.8% | |||
| Bihua Chen | 6.8% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
Boary Investment Co. Ltd.
13G
|
4.8% |
4/29/2025
Event 10/3/2023
|
||
| Boary Investment Co. Ltd. | 4.8% | |||
| Suzhou Baoruiheng Venture Capital Partnership | 4.8% | |||
| Xiamen Biotime Biotechnology Co., Ltd. | 4.8% | |||
| Xiamen Baotai Holding Group Co., Ltd. | 4.8% | |||
| Xiamen WangChen Health Industry Co., Ltd. | 4.8% | |||
| Zhang Guofeng | 4.8% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
4.4% |
8/14/2026
Event 6/30/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 4.4% | |||
| VHCP Co-Investment Holdings III, LLC | 4.4% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 4.4% | |||
| VHCP Management III, LLC | 4.4% | |||
| VHCP Management EG, LLC | 4.4% | |||
| Nimish Shah | 4.4% | |||
| Bong Y. Koh | 4.4% | |||
|
Hangzhou Jingyin Investment Partnership (Limited Partnership)
13G/A
|
2.9% |
5/14/2026
Event 12/31/2023
|
||
| Jin Yin (Bvi) Limited | 2.9% | |||
| Shanghai Gaopei Duwei Biotechnology Co., Ltd. | 2.9% | |||
| Hangzhou Jingyin Investment Partnership (Limited Partnership) | 2.9% | |||
| Hangzhou Jingfeng Investment Management Company | 2.9% | |||
| Shijun Feng | 2.9% | |||
|
Unique Mark Ventures Ltd
13G/A
|
0% |
2/9/2026
Event 12/9/2025
|
||
| Unique Mark Ventures Ltd | 0% | |||
| Fine Process Limited | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.60 k | $25.1 k |
| 2026 Q2 | 42 | 26.5 M | $304 M |
| 2026 Q1 | 26 | 11.6 M | $80.2 M |
| 2025 Q4 | 5 | 55.9 k | $79.3 k |
| 2025 Q3 | 5 | 16.4 k | $29.3 k |
| 2025 Q2 | 5 | 59.7 k | $88.2 k |
| 2025 Q1 | 5 | 56.6 k | $114 k |
| 2024 Q4 | 4 | 56.9 k | $133 k |
| 2024 Q3 | 4 | 63.7 k | $127 k |
| 2024 Q2 | 4 | 59.0 k | $197 k |
| 2024 Q1 | 4 | 60.4 k | $514 k |
| 2023 Q4 | 4 | 63.0 k | $560 k |
| 2023 Q3 | 4 | 48.3 k | $853 k |